Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
5.25
-0.04 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
5.44
+0.19 (3.56%)
After-hours: Dec 5, 2025, 7:51 PM EST
Evaxion Revenue
Evaxion had revenue of $7.49M in the quarter ending September 30, 2025, with 148.33% growth. This brings the company's revenue in the last twelve months to $7.65M, up 132.17% year-over-year. In the year 2024, Evaxion had annual revenue of $3.34M with 4,480.82% growth.
Revenue (ttm)
$7.65M
Revenue Growth
+132.17%
P/S Ratio
3.19
Revenue / Employee
$166,304
Employees
46
Market Cap
43.59M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EVAX News
- 23 days ago - Evaxion announce 2026 financial calendar - GlobeNewsWire
- 4 weeks ago - Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 - GlobeNewsWire
- 4 weeks ago - Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Evaxion announces business update and third quarter 2025 financial results - GlobeNewsWire
- 4 weeks ago - Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate - GlobeNewsWire
- 5 weeks ago - Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire
- 5 weeks ago - Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 - GlobeNewsWire
- 5 weeks ago - Evaxion raises $7.2 million, extending cash runway to second half of 2027 - GlobeNewsWire